In conclusion, treatment with evocalcet improved the achievement rate of the serum cCa target, decreased FGF23 levels by suppressing FGF23 synthesis, and decreased the incidence of hypocalcemia in the presence of VDRA, demonstrating the additive benefits of the combination therapy in SHPT patients. Here, FGF23 is linked to Hypocalcemia.